A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07339176

Title field or adapter rule

{'original_value': 'A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:30.454890+00:00

Published At

2026-10-21T00:00:00+00:00

Record Updated At

2026-10-21

Source Retrieved At

2026-10-31T22:19:02.163121+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Neoplasms, Solid Tumor", "Breast Neoplasms, Triple-Negative", "Squamous Cell Carcinoma of Skin", "Melanoma", "Head and Neck Neoplasms", "Carcinoma, Squamous Cell", "Carcinoma, Non-Small-Cell Lung"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-21", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07339176"

protocolSection.identificationModule.officialTitle

"A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Neoplasms, Solid Tumor (protocolSection.conditionsModule.conditions)
• Breast Neoplasms, Triple-Negative (protocolSection.conditionsModule.conditions)
• Squamous Cell Carcinoma of Skin (protocolSection.conditionsModule.conditions)
• Melanoma (protocolSection.conditionsModule.conditions)
• Head and Neck Neoplasms (protocolSection.conditionsModule.conditions)
• Carcinoma, Squamous Cell (protocolSection.conditionsModule.conditions)
• Carcinoma, Non-Small-Cell Lung (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['N17350 Intratumoral Injection 1 mg/ml superficial lesions', 'N17350 Intratumoral Injection 2 mg/ml superficial lesions', 'N17350 Intratumoral Injection 2 mg/ml visceral lesions', 'N17350 Intratumoral Injection 4 mg/ml superficial lesions', 'N17350 Intratumoral Injection 4 mg/ml visceral lesions', 'N17350 Intratumoral Injection for Melanoma', 'N17350 Intratumoral Injection for NSCLC', 'N17350 Intratumoral Injection for SCCHN', 'N17350 Intratumoral Injection for TNBC', 'N17350 Intratumoral Injection for cuSCC'], 'description': 'N17350 is a recombinant mutant porcine pancreatic elastase (PPE) developed to target the neutrophil elastase (ELANE) pathway.', 'name': 'N17350', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.